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Identity 
Other names: PRSS6; SCCE; hK7; hSCCE 
HGNC (Hugo): KLK7 
Location: 19q13.33 
Local order: Telomere to centromere. 
DNA/RNA 
Description 
The gene encompasses 6.509 kb of gDNA. 
Transcription 
Five variant mRNA transcripts have been identi-fied. 
These include transcripts using different 5' untranslated 
regions (UTRs) including exon 1 deletions, and 
transcripts using different 3'UTR regions. Using rapid 
amplification of cDNA ends (RACE) different KLK7 
5'UTR sequences were identified from RNA extracted 
from pancreas, skin  
and ovarian cells, suggesting the expression of tissue 
specific KLK7 transcripts. 
Pseudogene 
Not identified. 
Protein 
Description 
Full-length KLK7 (253 amino acids) has a secretion 
signal (pre-) peptide (22 amino acids), followed by an 
activation (pro-) peptide (7 amino acids) and the mature 
chain (224 amino acids) with 1 potential N-linked 
glycosylation site. The catalytic triad of His70, Asp112 
and Ser205 (relative to ATG1) is conserved and is 
essential for proteolytic activity. After synthesis as a 
KLK7 full-length protein, the signal peptide is then 
cleaved and pro-KLK7 (zymogen) is subsequently 
secreted from the cell. On activation, the propeptide is 
removed and the zymogen becomes the mature active 
enzyme.  
 
Genomic and protein structure of the KLK7 gene. The KLK7 gene is classically comprised of 5 coding exons (red boxes, classic 
numerals) and 4 intervening introns with a conserved intron phase pattern (I, II, I, 0). A non-coding exon and untranslated regions are 
shown in yellow. Also shown is the classical transcription initiation site (TIS) and corresponding translation start site (ATG1). An exon 1 
deleted transcript has also been identified which would potentially result in the use of an alternative translation start site (ATG2). The 
numbering for the amino acid residues of the catalytic triad (His70, Asp112, Ser205) are relative to the full-length protein starting from ATG1. 
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KLK7 can complex with antileukoprotease (secretory 
leukocyte protease inhibitor), elafin, Lympho-epithelial 
Kazal type inhibitor (LEKTI) fragments, and a member 
of a2-macroglobulin (a2M) protease inhibitor family, 
a2-macroglobulin-like 1 (a2ML1). 
X-ray structures of recombinant full-length KLK7 from 
E. coli and insect cells have been solved, from which 
the most distinguishing features of KLK7 are the short 
70-80 loop and the unique S1 pocket, which prefers P1 
Tyr residues. KLK7 displays a unique chymotrypsin-
like specificity for Tyr, which is preferred at P2. In 
addition, KLK7 exhibits large positively charged 
surface patches, representing putative exosites for 
prime side substrate recognition. 
Similar to several other KLKs and based on the binding 
of metal to histidine such as His99, the KLK7 activity is 
inhibited by Zn
++
 and Cu
++
 at low micromolar 
concentrations. KLK7 induced degradation of 
corneodesmosin and desmocollin 1 with similar 
efficiency in acidic (pH 5.6) and neutral (pH 7.2) 
conditions. KLK7 activity is modulated by water 
content in stratum corneum as KLK7 activity increased 
significantly in an environment of high relative 
humidity. KLK7 also demonstrated a tolerance to water 
restriction suggesting that it may be adapted to function 
in the water-restricted stratum corneum. Thus, relative 
humidity modulates desquamation by its effect upon 
KLK7 activity, possibly other desquamatory hydrolases 
and adapted KLK7 function in water-deplete skin. 
An N-terminal truncated KLK7 isoform (181 amino 
acids) initiating from the putative ATG2 would not 
have the pre-pro-region and 43 amino acids from the 
N-terminus of full-length KLK7. The histidine which is 
part of the catalytic triad is also omitted which would 
result in a proteolytic inactive protein. The presence of 
this isoform has not yet been confirmed in human 
tissues or biological fluids. 
Expression 
Full-length KLK7 protein was originally purified in 
human skin and named stratum corneum chymotryptic 
enzyme (SCCE, hSCCE). KLK7 cDNA was originally 
isolated from a keratinocyte derived library and 
designated PRSS6. Although Northern blot analyses 
have shown that KLK7 mRNA is predominantly 
localised to skin and pancreas, more sensitive RT-PCR 
experiments have shown that brain, kidney, ovary, 
bone, breast, endometrium, spinal cord, lung, prostate 
tissue and salivary tissue express KLK7 mRNA at low 
to modest levels. High KLK7 mRNA has been detected 
in malignancies of ovary, breast, lung and brain. 
KLK7 protein has been detected by ELISA in a wide 
range of tissues at low (adrenal, bladder, cervix, 
fallopian tube, kidney, lung, lymph node, muscle, 
ovary, salivary gland, small intestine, spinal cord, 
spleen, thyroid gland, tonsil, trachea and vagina) to 
high (oesophagus, heart, liver and skin) levels. Modest 
levels of KLK7 protein have also been detected in 
human body fluid, such as, seminal plasma, breast 
milk, ovarian cancer ascites, salivary and 
cervicovaginal fluid. 
In normal skin, KLK7 is expressed in late epidermal 
differentiation and found at all sites of epithelial 
cornification. Consequently, KLK7 is used as a marker 
for terminal epidermal differentia-tion. In normal 
epidermis, KLK7 was detected in a population of 
dendritic cells and in high suprabasal keratinocytes. 
KLK7 was also found in reconstruct-ted human 
epidermis and its expression was suppressed by retinoic 
acid. An increased expres-sion of KLK7 was found in 
suprabasal cells in orthokeratotic and parakeratotic 
areas of the lesions of oral lichen planus (an 
inflammatory disease) and benign oral keratosis (a non-
inflammatory disease). 
High KLK7 protein levels have been detected in the 
tissues of lung, breast, ovarian and squamous cervical 
cancers, oral squamous cell carcinoma and cervical 
adenocarcinoma tissues from patients. However, KLK7 
is down regulated in cancerous prostate tissues 
compared to normal prostate tissues. KLK7, along with 
KLK6 and KLK10, is decreased in cerebrospinal fluid 
of frontotemporal dementia patients. 
Localisation 
Full-length KLK7 is localised intracellularly in the 
cytoplasm prior to secretion. KLK7 protein is co-
localised with KLK5 in skin and acinar cells of the 
pancreas by immunohistochemical staining. 
The putative N-terminal truncated KLK7-181 isoform 
is potentially not secreted as it does not have a signal 
peptide, and cellular localisation remains to be 
determined. 
Function 
To date, the major biological functions of KLK7 are 
associated with the skin and related epithelial tissues, 
such as hair follicles, oral mucosa and glandular 
lobules. KLK7 is involved in keratiniza-tion, stratum 
corneum formation, and turnover/ desquamation of the 
skin through the degradation of cell adhesion 
glycoproteins, such as corneodes-mosin, desmocollin 1 
and plakoglobin. KLK7 has also been shown to cleave 
insulin B chain, degrade fibronectin, fibrinogen and 
interleukin 1beta (IL-1b), as well as activate pro-IL-1b. 
KLK7 and KLK5 can control activation of the human 
cathelicidin precursor protein, hCAP18, implying their 
ability to control innate immune defence. 
An in vitro study showed that UVB radiation can 
increase KLK7 and KLK5 expression at both mRNA 
and protein levels in keratinocyte (HaCat) cells. In the 
epidermis, the major inhibitor of KLK7, 
antileukoprotease (secretory leukocyte protease 
inhibitor) is produced by keratinocytes and can inhibit 
detachment of corneocytes from human plantar callus 
in vitro, while a weaker KLK7 inhibitor, elafin (skin-
derived antileukoprotease), can reduce the shedding of 
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corneocytes. Established epidermal mouse models 
overexpressing KLK7 have been shown to develop 
chronic itchy dermatitis. Further characterisation of 
these models also revealed epidermal 
hyperproliferation, decreased skin barrier function, and 
decreased expression of MHC II antigen in 
keratinocytes. These data provide an in vivo 
pathophysiological foundation that KLK7 plays an 
important role in skin, such as listed those below. 
KLK cascade activation systems have been des-cribed. 
KLK7 is activated by KLK5 and KLK12. KLK7 
activates other members of the kallikrein-related 
peptidase family including KLK1, KLK2, prostate 
specific antigen (PSA/KLK3) and KLK9. 
The function of the putative N-terminal truncated 
KLK7 remains to be established. 
Homology 
At the protein level, KLK7 shares 28% (KLK12), 33% 
(KLK9), 36% (KLK10, 11), 37% (KLK1, KLK3/PSA), 
38% (KLK2, KLK5, KLK6, KLK13), 40% (KLK8), 
41% (KLK14), 43% (KLK4) and 42.6% (KLK15) 
sequence homology with other members of the 
kallikrein-related peptidase family. 
Mutations 
Germinal 
An AACC insertion in the 3'UTR of the KLK7 gene 
has been found, which altered the common allele 
AACC to the rare allele AACCAACC. This insertion 
was found to be associated with atopic dermatitis. 
Implicated in 
Endocrine related cancers 
Disease 
It has been postulated that KLK7 plays a role in 
endocrine related cancers given its (a) dysregulated 
expression in cancerous tissues compared to normal 
tissues, (b) regulation by hormones, such as, oestradiol, 
progestins and glucocorticoids and (c) potential roles in 
degradation of cell-cell adhesion proteins, extracellular 
matrix (ECM) proteins and activation of other 
proteases and growth factors. 
Epithelial ovarian carcinoma (EOC) 
Disease 
Kallikrein 7 is highly expressed in serous EOC at both 
the mRNA and protein levels, and high KLK7 mRNA 
expression is associated with poorly differentiated, late 
clinical stage ovarian carcinomas and the volume of 
residual tumour after surgery. Upregulated KLK7 
protein was detected in EOC patient sera and tumour 
cytosols using ELISA, and in EOC tissue sections 
using immunohistochemis-try and a quantitative 
automated in situ immuno-fluorescence-based protein 
analysis. At the mRNA level, both KLK7 and its exon 
1 deleted short KLK7 transcripts were detected in 
serous EOC cells, while none or only KLK7 short 
transcript was found in normal ovarian epithelial cells. 
In addition, a coordinated expression pattern and co-
localisation of KLK7 and KLK5 were found in serous 
EOC cells suggesting a proteolytic cascade between 
them. Co-overexpression of KLK4, KLK5, KLK6 and 
KLK7 in ovarian cancer cells (OV-MZ-6) led to 
increased invasion in vitro and resulted in increased 
tumour burden in nude mice. A coordinated expression 
of KLK7 and protease inhibitor antileukoprotease was 
also found in EOC cells. Of interest, the 110-139 amino 
acid region of the KLK7 protein incorporates multiple 
CD8
+
 CTL and CD4
+
 helper T cell epitopes, and 
represents an attractive target antigen for 
immunotherapy of ovarian cancer. 
Prognosis 
EOC patients with KLK7 mRNA or protein expression 
in their tumours had a significantly shorter disease-free 
survival time than those with KLK7 negative tumours. 
KLK7 is an independent unfavourable predictor of 
disease-free and overall survival for patients with low 
grade cancers. KLK7 has been shown to increase 
specificity for diagnosis and prognosis of EOC in 
conjunction with other biomarkers, such as CA125, 
HE4 and B7-H4. 
Breast cancer 
Disease 
KLK7 gene expression was significantly lower in 
tumour tissues from early stage (I/II) breast cancer 
patients and tumour cells with progesterone receptors. 
Prognosis 
Two groups have reported conflicting data regarding 
the prognoses for breast cancer patients and KLK7 
expressing tumours. One study found that breast cancer 
patients with KLK7 positive tumours have relatively 
shorter disease-free survival and overall survival than 
patients with KLK7 negative tumours. However, 
another study reported that breast cancer patients with 
KLK7 expressing tumours have favourable outcomes 
compared to those with KLK7 negative tumours. 
Cervical cancer 
Disease 
In a study of 18 cervical cancer cell lines (10 primary 
and 8 established cell lines) and 8 normal cervical 
keratinocyte cell lines, KLK7 mRNA expression was 
detected in the cancer cells (5/10 primary and 4/8 
established lines) but not in any of the normal cervical 
keratinocytes. Interestingly, all five patients, who 
harbour KLK7 positive tumours that were used to 
establish the primary cell lines, were found to have 
metastatic involvement of the pelvic tumour draining 
lymph nodes. In the same study, tumour restricted 
expression of KLK7 was confirmed by 
immunohistochemistry staining in 4 of the 5 primary  
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squamous cervical tumours, and 1 of the 4 primary 
adenocarcinomas, but none of the normal cervical 
epithelial cells. Another immuno-histochemical study 
showed a significantly higher expression of KLK7 in 
cervical adenocarcinomas compared to normal 
endocervical glands. 
Pancreatic cancer 
Disease 
KLK7 is expressed in normal pancreas at mRNA and 
protein levels, and KLK7 protein is localised in acinar 
cells of the pancreas by immunohistoche-mical 
staining. KLK7 is overexpressed in pan-creatic 
adenocarcinomas at both the mRNA and protein levels. 
KLK7 expression was also observed in neoplastic cells 
of all tumours examined using immunohistochemistry 
with moderate-to-intense staining in 16 of the 23 
tumours examined. Only 2 of the 13 nonmalignant 
tissue specimens displayed moderate KLK7 staining, 
whereas the remaining specimens showed weak 
immunoreactivity. In pancreatic cancer cells, KLK7 
was shown to i) cleave desmoglein 2, ii) cleave E-
cadherin and the ECM protein, fibronectin, iii) enhance 
urokinase-type plasminogen activator receptor 
shedding, and iv) reduce cell aggregation and adhesion 
to vitronectin to promote pancreatic cancer invasion. 
Oral squamous cell carcinoma (OSCC) 
Disease 
cDNA microarray analysis revealed that KLK5, KLK7, 
KLK8 and KLK10 were upregulated in tumour samples 
versus normal controls. RT-qPCR analysis confirmed 
that KLK7 mRNA was most differentially regulated 
with a 5.3-fold increase, while 2.8-, 4.0- and 3.5-fold 
increases were observed for KLK5, KLK8, and 
KLK10, respectively. Immunohistochemical analysis 
demonstrated strong reactivity for all 4 KLK proteins in 
both orthotopic murine tumours and human OSCC 
tissues. 
Lung cancer 
Disease 
KLK7 mRNA levels are decreased in adenocarci-noma 
compared to matched nonmalignant lung tissue. 
Similarly, sera of patients with non-small cell lung 
cancer (NSCLC) have lower protein levels of KLK7, 
KLK5, KLK8, KLK10 and KLK12 than those from 
normal subjects. However, a study has reported intense 
cytoplasmic staining for KLK7, KLK5, KLK6 and 
KLK8 in 40-90% of squamous cell carcinomas, small 
cell carcinomas and carci-noid tumours while 20% of 
tumour cells had intense nuclear staining for KLK7, 
KLK5 and KLK8. 
Brain tumours 
Disease 
RT-qPCR analysis showed that KLK7 mRNA 
expression in intracranial tumours was associated with 
shorter overall survival than those tumours with no 
KLK7 expression from a survival analysis study of 73 
patients with intracranial tumours. Overexpression of 
KLK7 protein by cultivated brain tumour cells 
significantly enhanced the invasive potential in a 
Matrigel invasion assay. 
Colon cancer 
Disease 
One study using a semi-quantitative RT-PCR method 
showed that the KLK7 gene is up-regulated in colon 
cancer and its expression predicts poor prognosis for 
colon cancer patients. 
Skin disorders 
Note 
A majority of studies have concentrated on the 
concomitant functions of KLK7 and KLK5 in normal 
human skin and a number of skin disorders given its (a) 
high expression in pathological conditions compared to 
normal skin samples, (b) cleavage/degradation of 
intercellular adhesive glycolproteins and (c) potential 
of activation and degradation of cytokines, such as 
interleukin 1beta (IL-1b). 
Netherton syndrome (NS) 
Disease 
NS is a rare but severe inherited disorder that presents 
the three following characteristics with varying degrees 
of severity of their symptoms. 1) Ichthyosiform 
erythroderma - inflamed, red, scaly skin and 
trichorrhexis invaginata ("bamboo hair"). 2) Short, 
brittle, lustreless hair and atopic diathesis. 3) 
Predisposition to allergy problems. 
NS patients have mutations in the serine protease 
inhibitor Kazal-type 5 (SPINK5) gene, encoding the 
protease inhibitor LEKTI (lympho-epithelial Kazal-
type related inhibitor). Early studies using mouse 
models revealed that SPINK5-deficient mice mimic NS 
through degradation of desmoglein 1 by epidermal 
protease. The pathophysiological pro-cesses in the skin 
and epithelial related tissues of NS patients result from 
the lack of functional LEKTI protease inhibitor and 
consequently the over-degradation of 
corneodesmosomal cadherins by KLK7, KLK5 and 
KLK14. 
The SPINK5 gene is localised chromosome 5. SPINK5 
mutations introduce premature termination codons in 
LEKTI transcripts and lead to the production of 
truncated LEKTI forms that lack several inhibitory 
domains. NS is an autosomal recessive condition. 
Atopic dermatitis (AD) 
Disease 
AD is a chronic inflammatory and allergic skin 
disorder. Multifactorial studies have suggested that 
both genetic and environmental factors contribute to 
AD development. A study comprising 103 AD patients  
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and 261 matched controls revealed a significant 
association between the rare AACCAACC allele in the 
3'UTR of KLK7 with AD. However, another group 
found that the AACCAACC allele was not associated 
with AD in a cohort of 99 patients and 189 controls. 
Neverthe-less, patients with the AACCAACC allele 
have increased KLK7 protease activity resulting in 
premature breakdown of corneodesmosomes, and 
leading to impairment of the epidermal barrier. 
Furthermore, acute eczematous lesions and clini-cally 
unaffected skin can further increase produc-tion of 
KLK7 and epidermal barrier functions are damaged 
through environmental interactions, such as washing 
with soap and detergents, or long-term application of 
corticosteroids. A combination of the above factors 
leads to a defective skin barrier and increases the risk 
of allergen penetration and succeeding inflammatory 
reaction. By ELISA, KLK7 levels were found to be 
elevated in the stratum corneum of AD patients, and 
KLK7 in the serum significantly correlated with 
eosinophil counts in the blood of AD patients, 
indicative of the body under an allergic condition. 
Psoriasis 
Disease 
A number of early studies reported that the 
chymotrypsin-like activity in stratum corneum was 
slightly elevated in psoriasis, but KLK7 serum levels 
did not differ between normal volunteers and patients 
with psoriasis. It has been confirmed that KLK7 protein 
levels were similar between non-lesional and lesional 
skin extracts, but increased amounts of desmoglein 1, 
plakoglobin and high molecular weight fragments of 
desmocollin 1 were detected in the lesional skin, 
suggesting an involve-ment of other proteases. 
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